Etanercept: efficacy and safety for approved indications

Area of Science:

• Immunology
• Rheumatology
• Dermatology

Background:

• Etanercept is a biologic therapy targeting tumor necrosis factor alpha (TNF-α).
• It is approved for immune-mediated inflammatory conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis.

Purpose of the Study:

• To review the clinical efficacy and safety of etanercept.
• To consolidate data from various sources for a comprehensive overview.

Main Methods:

• Review of published clinical trials.
• Analysis of registry and post-marketing data.
• Inclusion of information provided by the manufacturer, Amgen.

Main Results:

• Etanercept is generally well-tolerated across its approved indications.
• The most frequent adverse event is injection site reaction, typically mild and self-limiting.
• Potential risks include increased susceptibility to infection, demyelinating disease, congestive heart failure, and malignancy.

Conclusions:

• Etanercept demonstrates a favorable safety profile with fewer patient withdrawals due to adverse events compared to other biologics.
• Pediatric data for etanercept is more extensive than for other biologics, suggesting potentially lower malignancy rates.
• It remains a valuable treatment option for various immune-mediated inflammatory diseases.